BIOHIT HealthCare is pleased to extend its corporate partnership with the British Laryngological Association (BLA) for a second year running, supporting its pursuit of improved diagnosis for laryngopharyngeal reflux (LPR). This two-way partnership enables the sharing of knowledge and expertise between the organisations at a number of exciting BLA events in the coming year, including the Cutting Edge Laryngology 2024 conference in October. At these events, members of the BLA will have the opportunity to learn how Peptest™ from BIOHIT can rapidly detect LPR in a primary care or clinic setting, helping to minimise waiting times for ENT referrals.
Mr Declan Costello, President of the BLA, commented: “We are delighted to have had BIOHIT’s dedicated support at many BLA events throughout 2023, and are looking forward to continuing this partnership into the new year.”
Graham Johnson, Managing Director of BIOHIT HealthCare, added: “We hope that the knowledge shared during this partnership will help us to better understand how Peptest can support the diagnostic pathway for LPR. Too often, reflux patients visit specialists with chronic extra-gastrointestinal symptoms that fall under ENT services. Peptest can provide a definitive diagnosis by measuring pepsin in the upper gastrointestinal and respiratory tracts, streamlining patient management.”
To find out more about Peptest, visit www.biohithealthcare.co.uk/biohit-product/peptest
